<DOC>
	<DOCNO>NCT00139880</DOCNO>
	<brief_summary>To test whether Parcopa , new Orally Disintegrating Tablet Carbidopa-Levodopa , faster onset action , change UPDRS Motor Exam score interval single dose Parcopa Sinemet compare 10 subject Parkinson 's disease . Subjects 40 year old idiopathic PD Hoehn Yahr state II III eligible take stable dose &lt; 200 mg carbidopa &lt; 2000 mg levodopa daily . At treatment visit , either Parcopa Sinemet , plus placebo opposite tablet ( ODT conventional ) administer . The dose subject 's prestudy regimen . The primary efficacy variable , time onset action , first postdose time 30 % decrease ( 30 % improvement ) total score achieve . All UPDRS evaluation do rater blind active treatment receive subject .</brief_summary>
	<brief_title>A Single Center , Randomized , Double-blind , Crossover Pilot Trial Comparing Onset Action Parcopa™ With Sinemet® Subjects With Stable Parkinson 's Disease</brief_title>
	<detailed_description>See approve Package Insert Adverse Event information .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Stable Parkinson 's disease idiopathic PD Hoehn Yahr state II III</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>